Using electromagnetic fields to balance oxygen levels for treating type 2 diabetes
Modulating ROS by Electromagnetic Fields to Treat Type 2 Diabetes
This study is looking at how certain electromagnetic fields might help improve health for people with type 2 diabetes by balancing out harmful substances in the body, potentially making it easier to manage blood sugar levels without any negative side effects.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Iowa NIH-funded |
| Lab location | 1 site (Iowa City, United States) |
| Project ID | NIH-11041082 on NIH RePORTER |
What this research studies
This research investigates how electromagnetic fields (EMFs) can modulate reactive oxygen species (ROS) to improve the health of individuals with type 2 diabetes (T2D). By applying specific EMF parameters, the study aims to reverse the redox imbalance that contributes to insulin resistance and glucose intolerance. Preliminary findings in mouse models and human cells suggest that this approach can enhance insulin sensitivity and lower blood sugar levels without adverse effects. The research seeks to provide a novel, non-invasive treatment option for managing T2D.
Who could benefit from this research
Good fit: Ideal candidates for this research are adults diagnosed with type 2 diabetes who struggle with insulin resistance and glucose management.
Not a fit: Patients with type 1 diabetes or those whose diabetes is not primarily related to insulin resistance may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could offer a new, effective treatment for type 2 diabetes that improves blood sugar control and insulin sensitivity.
How similar studies have performed: While the use of EMFs in this context is relatively novel, preliminary studies have shown promising results in reversing insulin resistance, indicating potential for success.
Where this research is happening
Iowa City, United States
- University of Iowa — Iowa City, United States (Active)
Researchers
- Principal investigator: Sheffield, Val C. — University of Iowa
- Study coordinator: Sheffield, Val C.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.